Neptune Technologies & Bioressources (CVE:NTB) Earns Daily Coverage Optimism Rating of 0.69

News coverage about Neptune Technologies & Bioressources (CVE:NTB) (NASDAQ:NEPT) has been trending somewhat positive on Sunday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Neptune Technologies & Bioressources earned a media sentiment score of 0.69 on their scale. InfoTrie also gave news coverage about the biotechnology company an news buzz score of 10 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the near future.

Neptune Technologies & Bioressources has a one year low of C$30.58 and a one year high of C$47.60.

About Neptune Technologies & Bioressources

Neptune Technologies & Bioressources Inc (Neptune) is a biotechnology company. The Company is engaged primarily in the development, manufacture and commercialization of marine-derived omega-3 polyunsaturated fatty acids (PUFAs). The Company operates in three segments: Neptune, Acasti Pharma Inc and Acasti Pharma Inc Its Neptune produces and commercializes nutraceutical products.

Read More: What is meant by a buy rating?

Receive News & Ratings for Neptune Technologies & Bioressources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neptune Technologies & Bioressources and related companies with MarketBeat.com's FREE daily email newsletter.